Antipsychotics May Not be Necessary for First-Episode Psychosis


Antipsychotics commonly cause a number of side effects including weight gain and long-term cardiovascular disease.

psychosis, psychiatry, therapy

Foregoing traditional antipsychotics could be beneficial for younger individuals suffering from psychosis.

A team, led by Shona M. Francey, Orygen, The National Center of Excellence in Youth Mental Health, examined whether intensive psychosocial intervention for first-episode psychosis in 15-25 year old patients could be managed in a specialized early intervention program for psychosis.

In the triple-blind randomized controlled non-inferiority study, the investigators looked at whether this treatment is non-inferior to standard treatment of antipsychotic medication combined with cognitive-behavioral case management delivered during the first 6 months of treatment for 90 individuals.

Each participant was randomized to receive either a placebo (n = 46) or antipsychotic medication (n = 44), with 33% of the participants in the trial medication arm finishing the entire six-month trial.

Eligible patients were required to have low-levels of suicidality and aggression, as well as a duration of untreated psychosis of less than 6 months and living in a stable accommodation with social support.

The investigators sought primary outcomes of the level of functioning as assessed by the Social and Occupational Functioning Scale (SOFAS) at 6 months.

The investigators found both groups improved on the SOFAS, with small group differences that were clinically trivial.

This indicates that treatment with placebo medication was no less effective than conventional antipsychotic treatment (mean difference, −0.2; 2-sided 95% confidence interval, −7.5-7.0; t = 0.060; P = 0.95).

“Within the context of a specialized early intervention service, and with a short [duration of untreated psychosis], the immediate introduction of antipsychotic medication may not be required for all cases of [first-episode psychosis] in order to see functional improvement,” the authors wrote. “However, this finding can only be generalized to a very small proportion of [first-episode psychosis] cases at this stage, and a larger trial is required to clarify whether antipsychotic-free treatment can be recommended for specific subgroups of those with [first-episode psychosis].”

Early intervention for psychosis usually involves a multicomponent treatment plan including a psychosocial therapies that have been shown to produce outcomes superior to treatment as usual. A central component of this treatment usually involves the provision of low-dose second-generation treatment of positive psychotic symptoms.

While effective, these medications can have direct and indirect negative impacts, with evidence supporting the efficacy of nonpharmacological interventions for psychosis increasing.

Recently, investigators found cognitive behavioral therapy (CBT) and family interventions in early intervention services could contribute to improved outcomes produced by the services.

In addition, the clinical staging model of psychiatric disorders shows that milder and simpler treatments are more impactful in the early course of the illness.

Antipsychotic medications are also linked to a number of adverse events, including weight gain, altered glucose metabolism, sexual dysfunction, long-term cardiovascular disease, and premature mortality. These concerns are even greater for first-episode patients who are younger, generally treatment naïve, and more susceptible to side effects and long-term impacts of medication.

Improved efforts at early detection may result in patients presenting at earlier stages and in less acute mental states, increasing the possibility of recovery through psychosocial support alone.

The study, “Psychosocial Intervention With or Without Antipsychotic Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial,” was published online in the Schizophrenia Bulletin Open.

Related Videos
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
Aaron Henry, PA-C, MSHS: Regaining Black Male Patient Trust in the Doctor's Office
Depression Screening: Challenges and Solutions at the Primary Care Level
What Should the American Academy of Physician Associates Focus on in 2025?
Danielle O'Laughlin, PA-C, MS: Navigating Long-Term Risks, Family Planning in PCOS
HCPLive Five at APA 2024 | Image Credit: HCPLive
John M. Oldham, MD: A History of Personality Disorder Pathology
Franklin King, MD: Psychedelic Therapy History, Advances, and Hurdles
Robert Weinrieb, MD: Psychiatry-Hepatology Approach for Alcohol-Related Liver Disease
© 2024 MJH Life Sciences

All rights reserved.